* Cytosorbents Corp CTSO.OQ CTSO.O is expected to show a
rise
in quarterly revenue when it reports results on November 7 for
the period ending September 30 2024
* The Princeton New Jersey-based company is expected to
report a
15.6% increase in revenue to $10.181 million from $8.81 million
a year ago, according to the mean estimate from 3 analysts,
based on LSEG data.
* LSEG's mean analyst estimate for Cytosorbents Corp is for
a
loss of 6 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for
Cytosorbents Corp
is $4.00, above its last closing price of $0.86.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Jun. 30 2024 -0.09 -0.10 -0.08 Beat 17.9
Mar. 31 2024 -0.12 -0.12 -0.12 Met 0
Dec. 31 2023 -0.10 -0.14 -0.13 Beat 5.5
Sep. 30 2023 -0.15 -0.14 -0.21 Missed -52.2
Jun. -0.11 -0.11 -0.14 Missed -24.4
30 2023
Jan. 1 0001 -0.13 -0.13 -0.17 Missed -34.2
Dec. 31 2022 -0.18 -0.17 -0.02 Beat 88.1
Sep. 30 2022 -0.16 -0.16 -0.28 Missed -70.7
This summary was machine generated November 6 at 14:33 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)